Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. (PCVX) completed concurrent equity and debt offerings on October 9, 2026. It issued $575 million aggregate principal amount of 1.50% convertible senior notes due October 15, 2032. Interest is payable semiannually beginning April 15, 2027. The initial conversion rate is 11.1607 shares per $1,000 principal amount, representing an approximately $89.60 per-share conversion price. Before July 15, 2032, holders may convert only upon certain events; from and after that date, they may convert at any time until close of business on the second scheduled trading day before maturity. Vaxcyte may settle conversions in cash, common shares or both, at its election.
The equity offering included 7,412,500 common shares at $64.00 each and pre-funded warrants for 400,000 shares at $63.999 each. Underwriters exercised in full an option for up to 1,171,875 additional common shares on October 7, 2026. Vaxcyte sold the offering securities. Net proceeds were approximately $544.3 million from equity and $558.7 million from debt, after underwriting discounts and commissions and estimated offering expenses payable by Vaxcyte.
Vaxcyte, Inc. (PCVX) is offering $500 million aggregate principal amount of 1.50% convertible senior notes due October 15, 2032, with an underwriters’ option exercisable within 30 days to buy up to $75 million more solely to cover over-allotments. Estimated net proceeds are approximately $485.8 million, or $558.7 million if the option is fully exercised. The notes pay 1.50% annual interest semiannually beginning April 15, 2027; initial conversion terms are 11.1607 shares per $1,000 principal amount, approximately $89.60 per share. Conversion before July 15, 2032 is available only under specified conditions, and Vaxcyte may elect cash, shares or a combination to settle conversions.
Vaxcyte is also offering 7,412,500 common shares and pre-funded warrants to purchase 400,000 shares, plus an underwriter option for up to 1,171,875 more shares in a separate offering; neither offering is contingent on the other. Vaxcyte expected to report preliminary cash, cash equivalents and investments of approximately $2.3 billion as of September 30, 2026. In Phase 3 OPUS-1, VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older and had a safety profile similar to PCV20 and PCV21; serotypes 3 and 12F versus PCV21 missed the prespecified noninferiority criterion but met the historical LBCI >0.5 threshold.
Vaxcyte, Inc. (PCVX) is offering 7,412,500 common shares and pre-funded warrants to purchase 400,000 shares, at $64.00 per share and $63.999 per warrant; the warrant exercise price is $0.001 per share. Estimated net proceeds are approximately $473.3 million, or approximately $544.3 million if underwriters fully exercise their option for 1,171,875 additional shares. Proceeds are intended to increase capitalization and financial flexibility.
A separate concurrent offering covers $500 million of 1.50% convertible senior notes due 2032, plus an underwriter option for up to $75 million; neither offering is contingent on the other. Preliminary, unaudited cash, cash equivalents and investments are expected to total approximately $2.3 billion as of September 30, 2026. In Phase 3 OPUS-1, VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older; in adults 18–49, two PCV21-shared serotypes missed the prespecified noninferiority criterion but met the historical threshold. The stated net tangible book value dilution for new investors is $43.49 per share.
Vaxcyte, Inc. executive Jim Wassil (EVP, Chief Scientific Ofc, COO) exercised options covering 18,000 shares of common stock at an exercise price of $5.35 per share on October 5, 2026, and sold 18,000 shares at $86.74 per share that day. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. The option was fully vested and exercisable, and the reported position following exercise was 46,398 stock options.
Vaxcyte, Inc. (PCVX) SVP, Finance & CAO Elvia Cowan exercised a fully vested and exercisable stock option for 19,000 shares on October 5, 2026, at a $25.92 exercise price, acquiring 19,000 common shares. She sold 19,000 shares that day at $86.74 per share pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the exercise, Cowan reported 74,068 shares subject to stock options.
Vaxcyte, Inc. (PCVX) is offering convertible senior notes due 2032 alongside a separate common-stock or pre-funded-warrant offering; neither is contingent on the other. Cash interest is payable semiannually on April 15 and October 15, beginning April 15, 2027; the notes mature October 15, 2032 unless converted, redeemed or repurchased earlier. Conversion is limited to specified circumstances before July 15, 2032, and Vaxcyte may settle in cash, common stock or both. The notes are senior unsecured and structurally subordinated to subsidiary liabilities.
The offerings are intended to increase capitalization and financial flexibility. Vaxcyte expects approximately $2.3 billion in cash, cash equivalents and investments as of September 30, 2026, based on preliminary, unaudited information. No public market exists for the notes, and Vaxcyte does not intend to list them.
In Phase 3 OPUS-1, VAX-31 had a safety profile similar to PCV20 and PCV21 and met all co-primary immunogenicity endpoints in adults 50 and older. All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met prespecified noninferiority criteria. It met the primary immunobridging criterion in all 32 comparisons between adults aged 18–49 and 50–64; against PCV21, serotypes 3 and 12F missed the prespecified threshold but met the historical threshold.
Vaxcyte, Inc. (PCVX) is offering common stock and, for certain investors in lieu of shares, pre-funded warrants. Each warrant’s purchase price equals the public offering price per share minus $0.001, and its exercise price is $0.001 per share. Vaxcyte expects net proceeds from the offering; the stated principal purposes are to increase capitalization and financial flexibility. The concurrent convertible-note offering due 2032 is separate, and neither offering depends on completion of the other.
In Phase 3 OPUS-1, VAX-31 was well tolerated, with a safety profile similar to PCV20 and PCV21 at all ages studied. It met all prespecified co-primary immunogenicity endpoints in adults 50 and older, and all 28 serotypes shared with PCV20 and/or PCV21 met noninferiority criteria. The three VAX-31-unique serotypes and cross-reactive serotype 20B met the superiority criterion. Among adults 18–49, all 32 immunobridging comparisons met noninferiority; in comparisons with PCV21, 17 of 19 met the prespecified threshold, while serotypes 3 and 12F met the historical threshold.
Vaxcyte expects approximately $2.3 billion in cash, cash equivalents and investments as of September 30, 2026; the preliminary results are unaudited and not finalized.
Vaxcyte, Inc. officer Elvia Cowan reported a proposed sale of 19,000 common shares, with an aggregate market value of $1,648,060.00, on approximately October 5, 2026. UBS Financial Services, Inc. is named as the broker. The shares are listed as acquired from the issuer through exercise of stock options, with cash payment.
Vaxcyte, Inc. (PCVX) officer James Wassil reported a proposed sale of 18,000 common shares through UBS Financial Services Inc., at an aggregate market value of $1,561,320.00 and an approximate sale date of October 5, 2026. The shares are listed as acquired from the issuer through exercise of a stock option, with cash as the payment method.
Vaxcyte, Inc. (PCVX) reported positive topline results from OPUS-1, its pivotal Phase 3 adult trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. VAX-31 met all prespecified primary immunogenicity endpoints: all 32 immunobridging serotype comparisons met the noninferiority criterion (lower bound of the 95% confidence interval above 0.667), and all four comparisons involving three unique serotypes and cross-reactive 20B met the superiority criterion (lower bound above 2.0).
Among adults 50 and older, VAX-31 met the noninferiority criterion above 0.667 for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21; the two that missed that threshold met the historical threshold above 0.5. Vaxcyte reported that VAX-31 was well tolerated, with a safety profile similar to PCV20 and PCV21 across ages studied. The trial dosed 4,047 participants, including 3,572 aged 50 and older and 475 aged 18–49; immune responses were assessed one month after vaccination. OPUS-2 and OPUS-3 results are anticipated in the first half of 2027, supporting a planned Biologics License Application submission in the first half of 2028, subject to FDA review.